Home / Publication / A Pharmacokinetic/Viral Kinetic Model to Evaluate the Treatment Effectiveness of Danoprevir Against Chronic HCV

Publication

A Pharmacokinetic/Viral Kinetic Model to Evaluate the Treatment Effectiveness of Danoprevir Against Chronic HCV

A Pharmacokinetic/Viral Kinetic Model to Evaluate the Treatment Effectiveness of Danoprevir Against Chronic HCV

Author(s): Laetitia Canini, Anushree Chatterjee, Jeremie Guedj, Annabelle Lemenuel-Diot, Barbara Brennan, Patrick Smith, Alan Perelson

Year: October 16, 2014

Recommended for you

How Model-informed drug development rescue projects from a risky situation

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis

Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer

© 2025 Certara. All Rights Reserved. | Privacy policy